Padagis, a provider of extended topical and other specialty pharmaceuticals primarily to the United States and Israel, announced on Friday that it has introduced Tazarotene Gel and Methylphenidate Transdermal System.

Tazorac Gel 0.05% and 0.1% are intended to topically treat plaque psoriasis of up to 20% body surface area, while Tazorac Gel 0.1% is also intended for the topical treatment of subjects with facial acne vulgaris of mild to moderate severity.

Daytrana, a prescription central nervous system (CNS) stimulant, is intended for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

Padagis President, Pam Hoffman, said, 'Padagis enters as the second generic prescription product to launch in each of these markets, demonstrating our ability to select and execute on pipeline products that bring value to our customers and patients alike. Many thanks to the development, regulatory, supply chain and commercial teams at Padagis for their work on these important launches.'